Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Study of Ruxolitinib or Placebo in Metastatic Colorectal Cancer
2013-004714-18Phase 2Terminated
- Sponsor
- Incyte
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing Ruxolitinib + Regorafenib with Placebo + Regorafenib (2 arms). Primary endpoint: Overall survival. Started Sep 2014; status: terminated.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2013-004714-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004714-18.